Biological Products, (No Diagnostic Substances)
Inhibrx Biosciences, Inc. (INBX) stock: what's happening now, every material event decoded in plain English, P/E and valuation, analyst ratings, and insider buying and selling.
AllSight quality score: 55/100 — a percentile rank of Inhibrx Biosciences, Inc.’s fundamentals against Manufacturing peers.
Consensus: Buy from 5 analysts (Buy 3 · Hold 2).
Average price target: $245.00 (+229.6% vs $74.33); range $245–$245.
Wall Street analyst consensus, shown as context — not an AllSight view.
Open-market buys: 44 · Open-market sells: 30 · Net: −$88.1M
Cluster · 3 insiders buying.
Discretionary open-market purchases are the signal; grants, option exercises and Rule 10b5-1 scheduled trades are context, not counted in the balance. Facts only — not a recommendation. Source: SEC Form 4 filings on EDGAR.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!